The risk of rifampicin-resistant TB after drug-susceptible TB treatment.
作者信息
Shapiro A N, Moultrie H, Jacobson K R, Bor J, da Silva P, Scott L, Jenkins H E
机构信息
Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
出版信息
IJTLD Open. 2025 Mar 12;2(3):173-175. doi: 10.5588/ijtldopen.24.0552. eCollection 2025 Mar.
Abstract
摘要
相似文献
1
The risk of rifampicin-resistant TB after drug-susceptible TB treatment.药物敏感结核病治疗后发生耐利福平结核病的风险。
IJTLD Open. 2025 Mar 12;2(3):173-175. doi: 10.5588/ijtldopen.24.0552. eCollection 2025 Mar.
2
Surveillance of fluoroquinolones resistance in rifampicin-susceptible tuberculosis in eastern China with whole-genome sequencing-based approach.基于全基因组测序方法对中国东部地区利福平敏感肺结核患者氟喹诺酮类药物耐药性的监测
Front Microbiol. 2024 Jul 10;15:1413618. doi: 10.3389/fmicb.2024.1413618. eCollection 2024.
3
Whole-genome sequencing for surveillance of fluoroquinolone resistance in rifampicin-susceptible tuberculosis in a rural district of Shanghai: A 10-year retrospective study.上海农村地区利福平敏感结核病中氟喹诺酮耐药性的全基因组测序监测：一项 10 年回顾性研究。
Front Public Health. 2022 Sep 15;10:990894. doi: 10.3389/fpubh.2022.990894. eCollection 2022.
4
Distribution of multi-drug resistant tuberculosis in Ekiti and Ondo states, Nigeria.尼日利亚埃基蒂州和翁多州耐多药结核病的分布情况。
New Microbes New Infect. 2023 Oct 31;55:101192. doi: 10.1016/j.nmni.2023.101192. eCollection 2023 Oct.
5
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].[耐异烟肼或耐利福平结核病的特征及治疗结果]
Kekkaku. 2003 Oct;78(10):611-7.
6
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.用于检测成人肺结核及利福平耐药性的Xpert® MTB/RIF检测法
Cochrane Database Syst Rev. 2014 Jan 21;2014(1):CD009593. doi: 10.1002/14651858.CD009593.pub3.
7
Longitudinal Analysis of Prevalence and Risk Factors of Rifampicin-Resistant Tuberculosis in Zhejiang, China.中国浙江利福平耐药结核病的患病率及危险因素的纵向分析。
Biomed Res Int. 2020 Feb 12;2020:3159482. doi: 10.1155/2020/3159482. eCollection 2020.
8
Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine.基于线探针检测的分子检测对利福平耐药结核病患者个体化治疗的影响：来自乌克兰前瞻性 INNOVA4TB 队列研究的数据。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241249841. doi: 10.1177/17534666241249841.
9
Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.国家结核病规划中低收入国家结核病化疗原则。
Indian J Tuberc. 2020 Dec;67(4S):S16-S22. doi: 10.1016/j.ijtb.2020.11.010. Epub 2020 Nov 28.
10
[Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].A组耐利福平结核分枝杆菌对抗结核药物的耐药性研究
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Nov 12;46(11):1110-1117. doi: 10.3760/cma.j.cn112147-20230804-00046.
本文引用的文献
1
Risk factors for and timing of presumptive recurrent TB.疑似复发性结核病的危险因素和发生时间。
Int J Tuberc Lung Dis. 2024 Nov 1;28(11):527-533. doi: 10.5588/ijtld.24.0019.
2
Isoniazid-resistant tuberculosis: A problem we can no longer ignore.耐异烟肼结核：一个我们不能再忽视的问题。
PLoS Med. 2020 Jan 21;17(1):e1003023. doi: 10.1371/journal.pmed.1003023. eCollection 2020 Jan.
3
The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study.提高对异烟肼耐药结核病的检测和治疗水平对耐多药结核病流行率的影响：建模研究。
PLoS One. 2019 Jan 24;14(1):e0211355. doi: 10.1371/journal.pone.0211355. eCollection 2019.
4
Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study.南非耐多药结核病爆发未被世界卫生组织认可的商业检测方法检出：一项观察性研究。
Lancet Infect Dis. 2018 Dec;18(12):1350-1359. doi: 10.1016/S1473-3099(18)30496-1. Epub 2018 Oct 18.
5
Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence.在HIV-1感染率高且结核病共流行的环境中，利福平敏感型肺结核患者获得性异烟肼和利福平耐药的低发生率
J Infect Dis. 2017 Sep 15;216(6):632-640. doi: 10.1093/infdis/jix337.
6
High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?复治病例中耐多药和耐利福平结核病的高发生率：其来源何在？
BMC Infect Dis. 2017 Jan 6;17(1):36. doi: 10.1186/s12879-016-2171-1.
7
Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.一线药物治疗耐异烟肼结核病：系统评价和荟萃分析。
Lancet Infect Dis. 2017 Feb;17(2):223-234. doi: 10.1016/S1473-3099(16)30407-8. Epub 2016 Nov 17.
8
High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions.南部非洲既往接受过治疗的人群中普遍存在的结核病负担沉重，这表明有实施针对性防控干预措施的潜力。
Eur Respir J. 2016 Oct;48(4):1227-1230. doi: 10.1183/13993003.00716-2016. Epub 2016 Jul 7.
9
Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?既往有结核病患者的Xpert MTB/RIF检测结果：我们能否区分真阳性和假阳性结果？
Clin Infect Dis. 2016 Apr 15;62(8):995-1001. doi: 10.1093/cid/civ1223. Epub 2016 Feb 16.
10
The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study.成功治疗后复发和再感染结核病的时间动态：一项回顾性队列研究。
Clin Infect Dis. 2014 Jun;58(12):1676-83. doi: 10.1093/cid/ciu186. Epub 2014 Mar 18.
Zotero 插件